Compare SPHL & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPHL | HCWB |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5M | 3.8M |
| IPO Year | 2024 | 2021 |
| Metric | SPHL | HCWB |
|---|---|---|
| Price | $5.81 | $1.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 5.9M | 69.7K |
| Earning Date | 12-29-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,956,226.00 | $422,026.00 |
| Revenue This Year | N/A | $178.64 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.92 | $0.95 |
| 52 Week High | $62.40 | $41.20 |
| Indicator | SPHL | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 55.18 | 41.21 |
| Support Level | $4.14 | $1.10 |
| Resistance Level | $25.11 | $1.44 |
| Average True Range (ATR) | 2.41 | 0.13 |
| MACD | 0.52 | 0.06 |
| Stochastic Oscillator | 19.65 | 69.19 |
Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment - in the development of construction projects. It derives maximum revenue from its Residential Customers.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.